Two Sigma Advisers
MRVI icon

Two Sigma Advisers’s Maravai LifeSciences MRVI Stock Holding History

Two Sigma Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-876,700
Closed -$2.85M – 1334
2025
Q4 		$2.85M Sell
876,700
-774,700
-47% -$2.61M 0.01% 1046
2025
Q3 		$4.74M Sell
1,651,400
-573,194
-26% -$1.46M 0.01% 766
2025
Q2 		$5.36M Sell
2,224,594
-13,406
-0.6% -$28.2K 0.01% 716
2025
Q1 		$4.95M Buy
2,238,000
+2,021,500
+934% +$7.99M 0.01% 799
2024
Q4 		$1.18M Sell
216,500
-453,000
-68% -$2.91M ﹤0.01% 1386
2024
Q3 		$5.56M Sell
669,500
-289,300
-30% -$2.5M 0.01% 674
2024
Q2 		$6.87M Sell
958,800
-404,000
-30% -$3.49M 0.02% 654
2024
Q1 		$11.8M Sell
1,362,800
-80,100
-6% -$542K 0.03% 484
2023
Q4 		$9.45M Sell
1,442,900
-290,600
-17% -$1.88M 0.02% 550
2023
Q3 		$17.3M Sell
1,733,500
-748,100
-30% -$8.21M 0.04% 344
2023
Q2 		$30.8M Buy
2,481,600
+974,500
+65% +$13.2M 0.08% 229
2023
Q1 		$21.1M Buy
1,507,100
+383,400
+34% +$5.51M 0.05% 319
2022
Q4 		$16.1M Buy
1,123,700
+665,400
+145% +$10.5M 0.04% 396
2022
Q3 		$11.7M Buy
458,300
+165,800
+57% +$4.16M 0.03% 460
2022
Q2 		$8.31M Buy
292,500
+176,000
+151% +$5.58M 0.02% 567
2022
Q1 		$4.11M Buy
116,500
+86,100
+283% +$2.89M 0.01% 892
2021
Q4 		$1.27M Buy
30,400
+24,800
+443% +$1M ﹤0.01% 1433
2021
Q3 		$275K Buy
+5,600
New +$273K ﹤0.01% 2146
2021
Q2 		– Sell
-57,600
Closed -$2.05M – 2601
2021
Q1 		$2.05M Buy
57,600
+600
+1% +$19.9K 0.01% 1254
2020
Q4 		$1.6M Buy
+57,000
New +$1.59M ﹤0.01% 1372

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers's MRVI Position: Q1 2026 in Review

Two Sigma Advisers sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 876,700 shares — an estimated $2.85M sold.

Two Sigma Advisers first reported a position in MRVI in Q4 2020 and held it in 20 quarters. The position peaked at $30.8M in Q2 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Two Sigma Advisers reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 876,700 Maravai LifeSciences shares in Q1 2026, an estimated $2.85M.
  • Two Sigma Advisers first reported a position in Maravai LifeSciences in Q4 2020 and held it in 20 quarters.
  • Two Sigma Advisers's Maravai LifeSciences position peaked at $30.8M in Q2 2023.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.